Nontraditional Antibiotics—Challenges and Triumphs
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (31 December 2019) | Viewed by 58322
Interests: antibiotics; antimicrobial resistance; polymyxins; peptide chemistry; peptide mimicry; drug discovery; organic synthesis
Special Issues, Collections and Topics in MDPI journals
In this Special Issue of Antibiotics, we invite submissions describing the latest developments in the design and preclinical evaluation of nontraditional antibiotics. Contemporary antibiotic discovery has hit a fork in the road—in one direction, we face major scientific obstacles preventing reinvigoration of the antibiotic pipeline using traditional approaches. Encouragingly, a paradigm shift is in motion to suggest that the alternative direction, involving nontraditional approaches, may assist in filling the void as we wait for new breakthroughs.
For example, phage lysins, antibodies and probiotics, amongst others, have been found to be of merit on the basis of technical feasibility, and the potential for high clinical impact. An estimated 30 nontraditional products are currently in clinical development. Indeed, the recent FDA approval of the first US clinical trial for bacteriophage-based therapy and the recent positive Phase II results of the lysin Exebacase provide much-needed optimism for the development of nontraditional therapies. The flipside is that the development of such products may face a host of new challenges associated with clinical trial design and regulation.
Therefore, this Special Issue aims to deliver an invaluable compendium of the latest approaches and challenges associated with the development of nontraditional antibiotics. Topics may include but are not limited to:
- Antibody/antibiotic conjugates;
- Narrow spectrum agents;
- Antibiotic inactivators;
- Antimicrobial peptides;
- Biofilm inhibitors;
- Virulence modulators.
Dr. Karl Hansford
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Nontraditional antibiotics
- narrow spectrum agents
- antibiotic inactivators
- antimicrobial peptides
- biofilm inhibitors
- virulence modulators